Objective: To know the natural history of the first wave of pandemic influenza A(H1N1)pdm09 in the Southern hemisphere, through the detection of antibodies against influenza A(H1N1)pdm09 in a selected community, to estimate the population attack rate and its variations, the consultation rates, hospitallization and mortality rates. Methodology: A representative random sample of the population of a commune in Chile (San Felipe) was interviewed and taken blood samples between January and March 2010. A study against the antibodies of the influenza A(H1N1) pdm09 virus was conducted, by the technique of the Hemaglutination Inhibition (HAI) according to standardized methodology. Subjects with antibody titers ≥1:40 were considered positive. Results: 13.5% of the population of San Felipe had antibodies against influenza A(H1N1)pdm09; this percentage reached 30% of the population between 0 and 18 years and 6.1% among those over 19 years. The age variable was the only factor that evidenced significant differences in the prevalence of antibodies. There were no significant differences related to gender, vaccination history against seasonal inluenza, or comorbidity. 51% of people with positive serology showed IN-FLUENZA-LIKE SYMPTOMS. Conclusions: A relevant percentage of subclinical disease was detected in the first pandemic wave in Chile and the proportion of people with SARI and deaths was small. Data from epidemiological surveillance were useful to estimate the trend of TSI but not its magnitude.
INTRODUCTION
Chile, along with other countries in the temperate zone of the southern hemisphere, was one of the first countries strongly affected by the influenza A(H1N1)pdm09 virus at the beginning of the pandemic wave. The first case was confirmed on May 17, 2009 and until December of the same year, 368,118 cases of influenza like illness(ILI) were notified in the whole country; 12,302 cases of specific PCR in real time were confirmed and 634,450 people from both the public and private health system were delivered for free antiviral treatments. During the same period, 1622 cases of severe acute respiratory infection (SARI) due to H1N1 (2009) and 150 deaths (deaths related to pandemic influenza) were confirmed. Among the cases of ILI, the highest rate corresponded to the 5 -14 year-old layer, followed by the <5 year-old layer; the ≥60 year-old layer showed the lowest rate. The pandemic influenza activity peaked between the epidemiological weeks (EW) 26 and 28, and then it declined and remain- In this context and considering the need to know the natural history of the first wave of pandemic H1N1(2009) influenza in the Southern hemisphere, the Ministry of Health in Chile through its Department of Epidemiology and the Panamerican Health Organization and the Centers for Disease Control and Prevention in Atlanta carried out a seroprevalence study at the end of the first pandemic wave. The aim was to detect antibodies against influenza A (H1N1) 2009 in a selected community, in order to estimate the population attack rate and its variations, the consultation rates, hospitalization and mortality rates, while describing the control measures implemented.
OPEN ACCESS
The study was designed and funded jointly by the three entities involved (Epidemiology-MINSAL-Chile, PAHO, CDC in Atlanta), including the payment of extra human resources, their training, the installation of a laboratory for RT-PCR in San Felipe town and the purchase of the necessary laboratory supplies for IFI and PCR-RT testing. The sample design was commissioned to the Center for Microdata of the Economics Faculty of the University of Chile; the gathering of in-situ information and samples was carried out by the Pediatrics Division and the Department of Public Health of the Pontifical Catholic University of Chile. The laboratory analysis was carried out by the Sub-Department of Virology at the Public Health Institute of Chile.
MATERIAL AND METHODS
The design corresponds to a cross-sectional analytical study by administrating a serological survey to a random and representative sample of the population of the San Felipe commune to measure the infection prevalence with the Influenza A(H1N1)pdm09 virus at the end of the first pandemic wave (January 2010). In order to carry out the study, San Felipe commune which is located 94 km northern Santiago in Chile (32˚45' South latitude 70˚43' West longitude) was chosen for having easy ways of access from Santiago, the capital city, and for having a small population and the 78% of them gets medical attention from the public health facilities in town. San Felipe has an area of 186 km2 and the population is of 75.412 inhabitants, 92% urban (estimate in 2009 by the NIS 1 ).The health infrastructure includes a base 226-bed hospital, an Emergency Primary Health Care Service, two urban General Practices Centers and a rural Primary Care Center. The Commune does not have private hospitals, only outpatient facilities of the Chilean Safety Association and of the Institute of Work Safety.
Sample-Size Calculation.
A stratified random sampling by age groups (0 -4 years old, 5 -18 years old and 19+ years old) was carried out, using the consumption of antiviral in the commune as the estimate of prevalence (attack rate); that is, given that in Chile free antiviral treatment was delivered to all people who suffered from a TSI and that the main of the influenza viruses circulating in 2009 was the influenza A(H1N1)pdm09 virus, it is possible to assume that the number of treatments provided are a good approximation to the number of the people who got ill. For the 0 -4 years old and 19+ years old strata, it was considered a 2% attack rate, a 1.5% absolute error and a 95% confidence level, while for the stratum 5 -18 years old, it was considered a 6% attack rate, a 2% absolute error and a 95% confidence level. The initial calculation of the sample size was amplified by 2.0 (design effect), reaching a sample size of 2.350 subjects, to which it was added 30% on account of oversampling (3.055 subjects) ( Table 1) .
0 -4 year-old and 5 -18 year-old stratum were over-represented while the 19+ was underrepresented in the sample. By expanding the sample, its composition by age was equal to the population of the commune of San Felipe.
Multistage Design and Registration. To ensure representative population, subjects were selected based on multistage random sampling; blocks were the primary sample units, dwellings were the secondary and people the tertiary. 3.077 dwellings were registered which produced a list of addresses to visit and subjects to contact during the field work.
The Instrument
A 35 question questionnaire was designed with information about demographic aspects identification, birth date, marital status, welfare, educational level, employment), clinical aspects (morbid history, pregnancy) and epidemiological information (influenza-like symptoms between May and September 2009, medical consultation, test taking, hospitalization, antiviral therapy, 2009 seasonal antiinfluenza vaccination history, people ill at home).
Ethical Aspects
The study was approved by an ad-hoc ethics committee constituted to review all the studies related to the 2009 Pandemic Influenza and by the Ethics Committee of the Pontifical Catholic University of Chile; it counted with an informed consent that had to be signed by everyone over 18 years old and the parents (or legal tutors) of minors, as well as the consent of children and adolescents etween 7 and 17 years old. b 
Funding
The study was funded by the Ministry of Health, the Panamerican Health Organization and the Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
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Field Work and Sampling
The field work was carried out in 8 weeks, from January to the first fortnight of March 2010. The samplings were taken by university-educated nurses through venous puncture in the crook of the elbow, collecting 10 ml (adults) or 5 ml (children under 30 kg). The samples were labeled and transported in cold chain to the commune hospital. The questionnaires were administered once the samples were taken.
Procedures and Laboratory Analysis
In the laboratory of the San Camilo Hospital of San Felipe, the samples were centrifuged to remove blood serum which was stored at −20˚C. Weekly, the samples were transferred to the Respiratory Viruses and Exanthematous Section of the Subdepartment of Clinical Virology of the Public Health Institute (PHI) where the study of the antibodies against the A(H1N1)pdm09 virus, by the technique of the hemagglutination inhibition (HI) according to standarized methodology [2] . The sera were previously treated with receptor destroying enzyme (RDE, vibrio cholerae Neuraminidase, Denka Seiken Corporation, Ltd., Tokio, Japón), incubated at 37˚C to inactivate nonspecific inhibitors of hemagglutination. The samples were then incubated at 56˚C for 30 minutes to inactivate the RDE.
As an antigen, a strain of the pandemic influenza A (H1N1) virus was used, the A/Santiago/34116/09 (H1N1) 20009, isolated from a patient in embryonated chicken eggs at the PHI an confirmed by RT-PCR in real time, using the primers and the recommended protocol by the CDC [3] .
The hemagglutination was carried out with turkey erythrocytes at a concentration of 0. The assay was performed in duplicate for each of the samples from an initial dilution of 1:10 to a final dilution of 1:1.280.
The results were recorded as titers or geometric medians corresponding to the reciprocal of the highest positive dilution.
In the present study, the proportion of subjects with antibody titers ≥1:40 were considered positive and termed seroprevalence.
Statistical Analysis
The statistical analysis was carried out using the module "Complex Samples" of the SPSS software, version 15.0. Two types of expansion factors were calculated: one for the subjects who completed the questionnaire and one for the subjects who provided blood samples. Not all the subjects who answered the questionnaire provided blood samples ( Table 1) .
The overall and specific antibodies prevalence as well as the clinical attack rate 2 , were calculated according to the age strata 3 . Those subjects who reported influenza like illness (fever above 38˚C with coryza or cough) between May 1 and September 1, 2009 were considered clinical cases. The subjects were classified into four stages according to the associated antibodies and the symptomatic illness: symptomatic seropositive, asymptomatic seropositive, symptomatic seronegative and asymptomatic seronegative. Odds ratios were calculated according to age strata (0 -4, 5 -18 y 19+ years old), sex, medical welfare (Fonasa, public sector/Isapre, private sector), 2009 seasonal anti influenza vaccine history and comorbidities (0, 1, ≥2 morbid history, as cancer, diabetes, asthma, heart diseases, COPD, hypertension, smoking, obesity, HIV/AIDS). A logistic regression model (EN-TER modality) was used for the adjustment of odds ratios. 2 Clinical attack rate = n˚of subjects with positive report of influenza like illness/total n˚ total of surveyed subjects * 100. 3 Global and specific prevalence of antibodies = n˚ of subjects with positive blood serum/total n˚ of blood sample donors In the same way, the rates of use of antiviral drugs, consultations and hospitalizations were calculated [4] in order to describe the access of the population to health services.
Based on the anti influenza A H1N1-2009 antibodies prevalence and the influenza like symptoms prevalence found in San Felipe, the theoretical number of subjects with anti influenza A H1N1-2009 positive serum for the total Chilean population [4] was estimated.
RESULTS
3.077 subjects were registered, 2.919 visits were made completing 2.450 questionnaires. This figure exceeded in 4.3% the estimated sample size ( Table 1) ; 2.190 subjects (89%) provided blood samples, being the 0 -4 year-old stratum the smaller group (74.6%). Table 2 shows the main demographic, clinical and epidemiological characteristics of the 2.450 subjects surveyed, according to age strata.
The population prevalence of antibodies against influenza 2009 A (H1N1) was 13.5% (CI 95%; 11.3 -15.9), reaching about 30% in the 0 -4 and 5 -18 year-old strata, while in those 19+ only reached 6.1%. Age was the only variable that showed significant differences in the prevalence of antibodies ( Table 3) .
Although the antibodies prevalence was higher among women than men, among homes of more than 5 people, among affiliated to FONASA 4 (as compared to those affiliated to ISAPRE 5 and among non vaccinated people against seasonal influence, these differences did not reach statistical signification ( Table 4) .
The prevalence among subjects that had influenzalike 6 symptoms between May-September 2009 was 32.2%; nonetheless, among people with positive antibodies, the influenza-like history nearly reached 51.5%, while it reached 30.3% among the people without antibodies ( Table 5) .
There was no significant association between history of vaccination against seasonal influenza and the presence of influenza-like symptoms; 33.6% of the people with vaccination history presented influenza-like symptoms versus the 31.5% of people without vaccination history. Although, in all ages the proportion of people with history of vaccination was bigger among those who had influence-like symptoms as compared to those who did not show any symptoms, the differences did not reach Neg. 14. statistical significance. 47% of subjects who reported influenza-like symptoms consulted for that cause. The proportion was higher among those with influenza positive serology, reaching 73% ( Table 6) .
Among these, children under 5 years old were those who showed the highest consultation rate (95%). However, the 19+ stratum showed a difference in the consul0 tation rate between the total sample and the seropositive subjects.
Regarding the use of antiviral, 2.7% (95% CI; 1.9 -3.9) of subjects who answered the survey received antiviral treatment, increasing to 11.5% (95% CI; 6.9 -18.4) among the seropositive subjects. In the first group (total subjects surveyed), the percentage decreased with age whereas among seropositive increased with age, reaching 15% among the 19+ year-old stratum ( Table 6 ).
Whereas 8 sample subjects were hospitalized, only one of them had anti-Influenza A(H1N1)pdm09 virus titers over 40.
DISCUSSION AND CONCLUSIONS
This is a population-based study representative of a Chilean commune (San Felipe).
The attack rate of the first pandemic wave was 13.5% in the same commune, with the highest rates among those under 18 years old, confirming the relevance of this group in the transmission of influenza in the community. Whereas the prevalence of antibodies was higher among non vaccinated people against seasonal influenza, it is not possible to confirm the relationship between those variables. Seropositive people had more influenza-like symptoms, consulted more and received more antiviral than the average population.
The results of this study showed that 73% of seropositive people consulted due to influenza-like symptoms and only 11% of them say they received antiviral treatment. This fact is outstanding considering the protocol instructed by the Ministry of Health who stated that all the people who consulted because of influenza-like symptoms would receive free antiviral treatment.
Considering in San Felipe age ETI rates and antiviral delivery were very similar to the national average, it is possible to assume that those results can be generalized to the rest of the country ( Table 7) .
According to this study, the pyramid of disease severity in San Felipe had a base of 13.5% people infected serologically (representing 10.181 people), 51.5% of the people with positive serology had symptoms caused by pandemic A(H1N1) influenza (which represents 7% of the total population); 73% of them consulted because of the symptoms (representing 5.1% of the commune population). Finally, 8 people from the sample were hospitalized for ILI, and only 1 had positive serology; there were no deceased people in the sample. World studies on antibody prevalence against 2009 A (H1N1) influenza show variable results. So, it is possible to find a 6% in Pune, India [5] , 15.7% among pregnant women in Manitoba, Canada [6] , 18.2% among under 15 years old in England [7] , 18.8% among non vaccinated people against H1N1 in China [8] , 29.5% in New Zealand [9] , 28.4% in Australia [10] , 29.7% in Taiwan [11] . The study carried out in the San Felipe commune shows an antibody prevalence relatively low as compared to other studies that have measured post pandemic prevalence of antibodies against influenza A(H1N1)pdm09 virus that could be partly explained by differences in the methodology to obtain the samples. In San Felipe it had a representative sample of the population base.
On the other hand, studies suggest that there would be a proportion of the population, especially older adults, with pre-existing immunity to the pandemic H1N1 virus (England), due to prior exposure to antigenically related viruses related to the influenza H1N1 virus that circu-lated the first half of the twentieth century. This pre-existing immunity varies from 0.9% in Pune, India [5] , 1.8% among under 5 years old to 31% among 80 yearold adults (England) [7] ; 12.8% in New South Wales, Australia [10] , 7.1% in Canada [11] , 11.9% in New Zealand [9] , 45% among >80 year-old subjects [12] , 24% among >65 year-old subjects [13] .
The latter estimate was not obtained in San Felipe, so obtained results could overestimate the real impact that the first pandemic wave had in that commune. On the other hand, it gives important information in terms of the structure of the pandemic severity, from subclinical infection and asymptomatic until the SARI. Furthermore, it gives evidence about the necessary considerations when interpreting the results of the epidemiological surveillance of influenza.
